This study tests a new drug combination for people with a type of slow-growing blood cancer called follicular lymphoma that has a high tumor burden. The treatment adds tazemetostat (a targeted pill) to a standard chemo-immunotherapy regimen, but uses a shorter course of chemother…
Phase: PHASE1, PHASE2 • Sponsor: Vaishalee Kenkre • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC